Shandong Jincheng Pharmaceutical Faces Evaluation Adjustment Amid Financial Challenges

Shandong Jincheng Pharmaceutical Group Co., Ltd. has recently undergone an adjustment in evaluation, reflecting shifts in its underlying financial metrics and market position. The company operates within the Pharmaceuticals & Biotechnology sector and is classified as a midcap entity. Recent data indicates that Shandong Jincheng has experienced a notable decline in its technical score, which has prompted a revision in its overall assessment. The technical indicators present a mixed picture, with the MACD showing a mildly bullish trend on a weekly basis, while the monthly perspective leans bearish. Additionally, the Bollinger Bands and moving averages suggest bearish conditions, indicating potential challenges in market performance. Financially, the company reported a very negative performance for the quarter ending September 2025, with net sales growing at an annual rate of just 0.03% and operating profit at 18.21% over the past five years. The operating cash flow reached its lowest point at CNY 279.64 million, and the return on capital employed (ROCE) was recorded at 2.1%. Furthermore, the stock has generated a return of -7.69% over the past year, with profits declining by 62.2%. This evaluation adjustment highlights the ongoing trends and challenges faced by Shandong Jincheng Pharmaceutical Group Co., Ltd. in a competitive market landscape. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.